SCHEMBL24136595

SCHEMBL24136595

Cc1c(O)c(O)c(Cl)c2c1C(=O)NCC2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACHE P22303 1/20 0.39
▸ PARP10 Q53GL7 7/20 0.36
▸ PARP11 Q9NR21 7/20 0.36
▸ PARP1 P09874 3/20 0.36
▸ CDC7 O00311 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ PTK2B Q14289 1/20 0.33
▸ NNMT P40261 2/20 0.32
▸ PIM1 P11309 2/20 0.32
▸ AURKB Q96GD4 2/20 0.32
▸ DAPK3 O43293 1/20 0.32
▸ DYRK3 O43781 1/20 0.32
▸ MAP4K4 O95819 1/20 0.32
▸ CDK1 P06493 1/20 0.32
▸ CDK2 P24941 1/20 0.32
▸ CSNK1A1 P48729 1/20 0.32
▸ CLK2 P49760 1/20 0.32
▸ GSK3A P49840 1/20 0.32
▸ GSK3B P49841 1/20 0.32
▸ IRAK1 P51617 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24136596 0.87 ACHE (0.39) ACHEPARP10PARP11PARP1CDC7
SCHEMBL30466436 0.87 ACHE (0.39) ACHEPARP10PARP11PARP1CDC7
SCHEMBL24136634 0.86 ACHE (0.43) ACHEPARP10PARP11PARP1HTT
SCHEMBL24136677 0.86 ACHE (0.43) ACHEPARP10PARP11PARP1CDC7
SCHEMBL30466416 0.86 ACHE (0.43) ACHEPARP10PARP11PARP1CDC7
SCHEMBL24136727 0.83 IMPDH2 (0.37) ACHEPARP10PARP11PARP1CDC7
SCHEMBL30466437 0.70 PARP10 (0.42) ACHEPARP10PARP11PARP1CDC7
SCHEMBL24136591 0.70 PARP10 (0.42) ACHEPARP10PARP11PARP1CDC7
SCHEMBL24136647 0.69 PARP10 (0.35) PARP10PARP11PARP1CDC7HTT
SCHEMBL30046575 0.69 PARP10 (0.35) PARP10PARP11PARP1CDC7HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113423710-B Novel heterocyclic tricyclic derivative compounds and use thereof 韩美药品株式会社 2024-06-14 — — CN disclosed
US-20220135582-A1 NOVEL HETEROTRICYCLIC DERIVATIVE COMPOUND AND USE OF SAME HANMI PHARMACEUTICAL CO., LTD. (KR) 2022-05-05 — — US disclosed
EP-3929199-A1 NOVEL HETEROTRICYCLIC DERIVATIVE COMPOUND AND USE OF SAME Hanmi Pharmaceutical Co., Ltd. (KR) 2021-12-29 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220135582-A1 NOVEL HETEROTRICYCLIC DERIVATIVE COMPOUND AND USE OF SAME EZH2, EZH1, BMI1 ACHE 4227/4885PARP10 499/4885PARP11 327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback